FSGS, TR-MCD, and DN Study

FSGS, TR-MCD, and DN Trials in Phoenix

Aventiv Research is currently participating in an FSGS, TR-MCD, and DN study at our Phoenix, AZ location. Currently, there are no approved therapies in the US to specifically treat Focal Segmental Glomerulosclerosis (FSGS) or Treatment Resistant Minimal Change Disease (TR-MCD). Despite current treatments for Diabetic Nephropathy (DN), patients continue to experience progressive loss of kidney function. Given this there is a need to develop new therapies to treat patients with FSGS, TR-MCD, and DN. Advances in drug therapy are key to treating these diseases in their early stages and preventing further damage.

Enroll Now

FSGS, TR-MCD, and DN Clinical Trial

The objective of this study is to evaluate the safety and efficacy of an investigational medication for the treatment of Diabetic Nephropathy (DN), Focal Segmental Glomerulosclerosis (FSGS), and Treatment Resistant Minimal Change Disease (TR-MCD). You may be be eligible to participate in this study if you:

• Are between 18 and 75 years of age
• Have been diagnosed with Diabetic Nephropathy (DN)

OR

• Focal Segmental Glomerulosclerosis (FSGS) AND Treatment Resistant Minimal Change Disease (TR-MCD)